Acrivon Therapeutics, Financials
| ACRV Stock | 6.55 0.11 1.71% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.32 | 9.7491 |
|
|
Investors should never underestimate Acrivon Therapeutics,'s ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Acrivon Therapeutics,'s cash flow, debt, and profitability to make informed and accurate decisions about investing in Acrivon Therapeutics, Common.
Net Income |
|
Acrivon | Select Account or Indicator |
Understanding current and past Acrivon Therapeutics, Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Acrivon Therapeutics,'s financial statements are interrelated, with each one affecting the others. For example, an increase in Acrivon Therapeutics,'s assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Acrivon Therapeutics,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Acrivon Therapeutics, Common. Check Acrivon Therapeutics,'s Beneish M Score to see the likelihood of Acrivon Therapeutics,'s management manipulating its earnings.
Acrivon Therapeutics, Stock Summary
Acrivon Therapeutics, competes with Aerovate Therapeutics, Adagene, Rezolute, AN2 Therapeutics, and Anebulo Pharmaceuticals. Acrivon Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US0048901096 |
| CUSIP | 004890109 |
| Location | Massachusetts; U.S.A |
| Business Address | 480 Arsenal Way, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.acrivon.com |
| Phone | 617 207 8979 |
Acrivon Therapeutics, Key Financial Ratios
| Return On Equity | -0.38 | ||||
| EBITDA | (59.85 M) | ||||
| Net Income | (60.39 M) | ||||
| Book Value Per Share | 5.38 X | ||||
| Market Capitalization | 200.52 M |
Acrivon Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Acrivon Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Acrivon Therapeutics, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Acrivon Therapeutics, competition to find correlations between indicators driving Acrivon Therapeutics,'s intrinsic value. More Info.Acrivon Therapeutics, Common is rated third in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At this time, Acrivon Therapeutics,'s Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Acrivon Therapeutics, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Acrivon Therapeutics, Systematic Risk
Acrivon Therapeutics,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Acrivon Therapeutics, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Acrivon Therapeutics, correlated with the market. If Beta is less than 0 Acrivon Therapeutics, generally moves in the opposite direction as compared to the market. If Acrivon Therapeutics, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Acrivon Therapeutics, is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Acrivon Therapeutics, is generally in the same direction as the market. If Beta > 1 Acrivon Therapeutics, moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Acrivon Therapeutics, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Acrivon Therapeutics,'s growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Acrivon Therapeutics, growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Acrivon Therapeutics, November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Acrivon Therapeutics, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Acrivon Therapeutics, Common. We use our internally-developed statistical techniques to arrive at the intrinsic value of Acrivon Therapeutics, Common based on widely used predictive technical indicators. In general, we focus on analyzing Acrivon Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Acrivon Therapeutics,'s daily price indicators and compare them against related drivers.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 22.84 | |||
| Value At Risk | (7.65) | |||
| Potential Upside | 7.66 |
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.